Cardiac implantable electronic devices in heart failure: needs, challenges, and real-world implementation Authors: David Žižek, Miha Mrak, Anja Zupan Mežnar, Maja Ivanovski, Tadej Žlahtič, Christopher F Barrientos, Andrew P Ambrosy, Zlatko Fras, Mauro Biffi, Mitja Lainscak Published: 2026 ABSTRACT AbstractCardiac implantable electronic devices (CIEDs) are integral to heart failure (HF) management, providing therapies for bradyarrhythmias, cardiac resynchronization therapy (CRT), sudden cardiac death (SCD) prevention, and remote monitoring. This review summarizes current and potential future indications, emerging technologies, and challenges in the implementation of CIEDs in HF. Conventional right ventricular pacing in HF patients is increasingly being replaced by biventricular pacing (BVP) and left bundle branch area pacing (LBBAP), while leadless pacing pacemakers have emerged as an alternative to conventional transvenous systems, offering the potential to reduce lead- and device-related complications. As BVP remains the standard approach for CRT, recent data bestow LBBAP as a promising alternative and integration platform. Newer implantable cardioverter-defibrillator technologies, including subcutaneous and extravascular systems, may reduce lead-related complications while maintaining effective arrhythmia termination and recognition. Advances in atrial fibrillation management, implantable hemodynamic monitoring, and novel pacing indications such as atrioventricular recoupling and personalized pacing in HF with preserved ejection fraction are expanding the therapeutic potential of CIEDs. However, the adoption of these innovations is challenged by limited randomized evidence, procedural complexity, and substantial disparities in access and implementation across healthcare systems. Ongoing clinical trials will help define the role of emerging device technologies and monitoring strategies, while efforts to improve guideline adherence, value-based procurement, and equitable access remain essential to maximize the benefits of CIED therapy in patients with HF.Graphical abstractHF – heart failure; LVEF – left ventricular ejection fraction; BVP – biventricular pacing; CSP – conduction system pacing; LP – leadless pacing; LBBAP – left bundle branch area pacing; RCT – randomized clinical trial; HFrEF – heart failure with reduced ejection fraction; CRT – cardiac resynchronization therapy; LOT-CRT – left optimized resynchronization therapy; AF – atrial fibrillation; TV-ICD – transvenous implantable cardiac defibrillator; SCD – sudden cardiac death; HFpEF – heart failure with preserved ejection fractionKeywords: Cardiac implantable electronic devices, Biventricular pacing, Conduction system pacing, Leadless pacing, Implantable cardioverter-defibrillator, Heart failure Introduction Cardiac implantable electronic devices (CIEDs) have undergone substantial evolution, extending well beyond traditional pacemaker therapy for arrhythmia management. In patients with heart failure (HF), CIEDs now represent a cornerstone of care, offering bradyarrhythmia treatment, cardiac resynchronization therapy (CRT), prevention of sudden cardiac death (SCD), and improvement of cardiac function. Contemporary devices increasingly incorporate sophisticated monitoring technologies that facilitate disease surveillance and optimize clinical decision-making [1]. This review highlights recent developments in CIEDs and HF, focusing on the latest scientific evidence, challenges in clinical implementation, and future directions. Methods This narrative review was based on a structured literature search of PubMed/MEDLINE and contemporary international guideline and consensus documents published up to the time of manuscript preparation. Search terms included combinations of heart failure, cardiac implantable electronic devices, cardiac resynchronization therapy, conduction system pacing, left bundle branch area pacing, His bundle pacing, leadless pacing, implantable cardioverter-defibrillator, remote monitoring, and atrial fibrillation. Priority was given to contemporary clinical practice guidelines, expert consensus statements, randomized controlled trials, meta-analyses, and large prospective registries. Landmark observational studies and ongoing clinical trials were included when they addressed emerging technologies or clinical questions for which randomized evidence is currently limited. The objective was to provide a balanced overview of established evidence, recent advances, and future directions in device therapy for heart failure. Contemporary indications for CIEDs in heart failure In patients with HF, CIED therapy may be indicated for the management of bradyarrhythmias, delivery of CRT, or prevention of SCD. Current evidence and clinical maturity of established and emerging CIED therapies in heart failure is summarized in Table 1. Table 1Current evidence and clinical maturity of established and emerging CIED therapies in heart failureDevice strategyMain evidence baseCurrent clinical positionResynchronization with biventricular pacing in HFMultiple landmark RCTs demonstrating reductions in HF hospitalization and mortalityStandard of careBiventricular pacing for prevention of PICMRandomized trials and guideline recommendationsStandard of careCSP for prevention of PICMObservational studies, registries, smaller randomized trials, ongoing large RCTsReasonable alternative in selected patientsCSP as alternative resynchroniztion strategySmall to medium-sized randomized trials with mixed resultsSelected patients, experienced centresCSP after failed biventricular resynchronization therapyObservational studies and expert consensusEstablished bail-out strategyCSP optimized biventricular resynchronization (e.g. LOT-CRT)Mechanistic studies and observational dataEmerging strategyLeadless pacingLarge observational studies and registry data, no RTCsEstablished alternative in selected patientsLeadless LV endocardial pacing (WiSE-CRT)Feasibility studies and limited prospective clinical dataAlternative expert-centre strategyBiventricular pacing after AVNA ablationRandomized trials and meta-analysesEstablished strategyCSP after AVNA ablationObservational studies, small RCTs and meta-analysesEmerging alternativeAV-optimized pacing for symptomatic prolonged PR intervalMechanistic studies and small randomized crossover trialsInvestigationalPersonalized accelerated pacing in HFpEFSmall prospective and randomized studiesInvestigationalTransvenous ICDMultiple landmark randomized trialsStandard of careSubcutaneous ICD (S-ICD)Large registries and comparative studiesEstablished alternativeExtravascular ICD (EV-ICD)Prospective pivotal studies and post-marketing dataEmerging alternativeModular leadless pacing-defibrillator systemsEarly clinical studiesInvestigationalMultiparametric device monitoring (e.g., HeartLogic)Prospective validation studies and observational dataEmerging clinical toolPulmonary artery pressure monitoring (CardioMEMS)Randomized outcome trialsEstablished option in selected HF patientsHF heart failure, RCT randomized clinical trial, CSP conduction system pacing, PICM pacing-induced cardiomyopathy, AV atrio-ventricular, LOT-CRT left bundle branch-optimized cardiac resynchronization therapy, HFpEF heart failure with preserved ejection fraction, ICD implantable cardioverter defibrillator Current evidence and clinical maturity of established and emerging CIED therapies in heart failure HF heart failure, RCT randomized clinical trial, CSP conduction system pacing, PICM pacing-induced cardiomyopathy, AV atrio-ventricular, LOT-CRT left bundle branch-optimized cardiac resynchronization therapy, HFpEF heart failure with preserved ejection fraction, ICD implantable cardioverter defibrillator Bradycardia pacing While indications for bradycardia pacing are consistent between patients with and without HF, the presence of ventricular dysfunction requires careful selection of pacing modality to avoid deterioration of left ventricular ejection fraction (LVEF) and the development of pacing-induced cardiomyopathy (PICM) [2, 3]. Accordingly, biventricular pacing (BVP) and conduction system pacing (CSP) are increasingly preferred over conventional right ventricular pacing (RVP) [4, 5]. The ESC clinical consensus statement on conduction system pacing and the HRS/APHRS/LAHRS consensus on cardiac physiologic pacing are largely concordant in emphasizing that the optimal pacing strategy depends on LVEF and the anticipated burden of ventricular pacing [4, 5]. In patients with a low expected ventricular pacing burden (< 20%) and preserved or mildly reduced LVEF (> 40%), conventional RVP with minimization algorithms is generally recommended, although CSP may be considered as an alternative physiologic pacing strategy, particularly in the setting of potential progression of conduction disease. In patients with a higher anticipated ventricular pacing burden and mildly reduced LVEF, both BVP and CSP may be considered as alternatives to RVP to reduce the risk of PICM [4, 5]. In patients with LVEF < 40%, ESC guidelines favour BVP, while CSP may be considered as an alternative, particularly when CRT delivery is challenging or when a less complex device strategy is preferred [2, 4]. Similarly, HRS/APHRS/LAHRS recommendations align these patients with CRT indications, with BVP remaining the preferred pacing modality in those with LVEF ≤ 35% [5]. Cardiac resynchronization CRT is indicated in patients with symptomatic heart failure, LVEF ≤ 35%, persistent symptoms despite optimal guideline-directed medical therapy (GDMT), and a widened QRS complex Importantly, CRT should be considered as part of a comprehensive HF treatment strategy. Optimization of contemporary GDMT remains essential before device implantation whenever feasible, as pharmacological therapy may improve ventricular function, symptoms, and overall prognosis [2, 5–7]. The magnitude of benefit and strength of recommendation are primarily determined by QRS morphology and duration [5, 6, 8]. CRT is recommended in patients in sinus rhythm with left bundle branch block (LBBB) and QRS duration ≥ 150 ms. It should also be considered in those with LBBB and QRS duration 130–149 ms, as well as in patients with non-LBBB morphology and QRS ≥ 150 ms. In patients with non-LBBB morphology and QRS duration 130–149 ms, CRT may be considered, albeit with a lower expected benefit [5, 6, 9]. In patients with atrial fibrillation, CRT is recommended, with the strongest evidence in those with NYHA class III–IV symptoms and QRS ≥ 150 ms [2, 6]. Consistent with these recommendations, real-world data indicate that atrial fibrillation is not associated with reduced CRT utilization and does not modify the association between CRT and lower risks of adverse clinical outcomes [10]. Achieving a high percentage of effective biventricular pacing is important, and atrioventricular node ablation (AVNA) may be considered when adequate pacing cannot otherwise be ensured, however, recent study did not show improvement in mortality or non-fatal HF events compared to medical rate control [2, 11]. In patients eligible for CRT, CSP may be considered as an alternative to BVP, either as a primary strategy in selected patients or when coronary sinus lead placement is unsuccessful or not feasible [2, 4, 5]. Although CSP has emerged as an important physiological pacing strategy, the strength of supporting evidence varies across different clinical indications. Conventional BVP remains the standard CRT approach for most eligible patients, supported by multiple landmark randomized trials demonstrating improvements in ventricular remodeling, heart failure outcomes, and survival, as well as by contemporary guideline recommendations [2, 5, 12, 13]. Consideration is warranted in patients who develop symptomatic PICM following conventional RVP. In such cases, device upgrade to CRT using either BVP or CSP is recommended in patients on optimal GDMT with LVEF ≤ 35%, and may also be considered in those with LVEF 35–40% [2, 14]. Prevention of sudden cardiac death Implantable defibrillator implantation for primary prevention is recommended in patients with symptomatic heart failure despite GDMT, ischemic cardiomyopathy, and LVEF ≤ 35%, and should be considered in comparable patients with non-ischemic cardiomyopathy. Contemporary GDMT has substantially improved outcomes in patients with HFrEF and may reduce the risk of ventricular arrhythmias and sudden cardiac death. Reassessment of left ventricular function following optimization of medical therapy therefore remains an important component of primary prevention ICD decision-making [15]. Candidates for ICD implantation should have a reasonable expectation of survival with good functional status for more than one year. In contemporary practice, ICD candidacy should additionally take into account competing non-arrhythmic mortality, frailty, major comorbidities, patient preferences, and anticipated quality-of-life benefit, particularly in older patients, those with improved LVEF, advanced heart failure, or significant non-cardiac disease [6, 9, 15, 16]. In patients with specific cardiomyopathies (e.g., hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, or cardiac sarcoidosis) or pathogenic variants associated with a high risk of sudden cardiac death, primary prevention ICD implantation may be indicated even when LVEF is > 35%; in such cases, disease-specific recommendations, risk algorithms, and validated risk scores should be applied when available [16, 17]. Although overall indications are largely concordant, ESC guidelines assign a weaker recommendation (Class IIa) for non-ischemic cardiomyopathy compared with the Class I recommendation in American guidelines [6, 9]. For primary prevention, ICD implantation is not recommended within 40 days following myocardial infarction. It is also generally not indicated in patients with advanced heart failure and severe symptoms unless CRT or advanced HF therapies are concurrently considered [6, 16]. ICD implantation for secondary prevention is indicated in patients who have survived sudden cardiac arrest or sustained hemodynamically significant ventricular arrhythmias in the absence of a reversible cause. These indications are consistent across contemporary European and American guidelines [17, 18]. Current evidence for pacing to prevent heart failure and conventional pacemaker-related complications Although conventional RVP effectively prevents bradyarrhythmias, implantation of transvenous (TV) pacemakers is associated with important long-term risks. Approximately 10% of patients experience complications within 5 years after conventional pacemaker implantation [19]. These complications can be broadly categorized as lead-related, device-related, and PICM. To reduce lead- and device-related complications, leadless pacemakers (LPs) were developed. Although randomized comparisons between conventional TV pacemakers and LPs remain limited, observational studies suggest that LPs may reduce device-related reinterventions, infections, and possibly even HF hospitalizations [1, 20]. However, LP implantation has also been associated with a higher risk of cardiac perforation compared with conventional pacemaker implantation, as well as suboptimal atrioventricular synchrony [21, 22]. An important long-term complication of non-physiological pacing is PICM. The reported incidence varies considerably, ranging from 6 to 25%, largely because of the absence of a standardized definition, uncertainty regarding the threshold defining a high RV pacing burden (typically ranging from 20 to 40%), and the lack of distinction between pacing-induced and pacing-related cardiomyopathy [3, 5]. Most studies define PICM as a decline in LVEF to < 50%. Strategies to mitigate PICM include BVP, which requires an additional coronary sinus lead, and CSP, in which the ventricular lead is positioned at the His bundle or within the left bundle branch area [23–25]. Current recommendations favour BVP over CSP in HF patients, primarily based on the results of the BLOCK HF randomized trial, which demonstrated that among patients with HF, LVEF ≤ 50%, and an anticipated high RV pacing burden, BVP was superior to RVP across several clinical outcomes [4, 26]. However, these findings were not confirmed in the BioPace trial, which predominantly enrolled patients with preserved LVEF and narrow QRS complexes [27]. More recently, CSP technique, particularly left bundle branch area pacing (LBBAP), which is technically more feasible than His bundle pacing (HBP), has emerged as a promising physiological pacing strategy capable of preserving or restoring near-normal ventricular activation [5] (Fig. 1). Evidence supporting LBBAP over RVP is currently derived mainly from observational studies suggesting improved survival in patients with a pacing indication and a high anticipated pacing burden [28–30]. Several smaller randomized trials have demonstrated better preservation of cardiac function with LBBAP, although they have not shown significant reductions in HF hospitalizations or mortality [31–33]. As implantation techniques and dedicated tools continue to evolve, the results of ongoing large, randomized trials (Table 1 and 2) and further refinements in procedural methodology will be crucial for the safe and effective implementation of LBBAP across centers with varying levels of expertise [37]. Pacing modalities in heart failure. Evolution of pacing and resynchronization modalities for prevention and treatment of heart failure. RV pacing—right ventricular pacing using leadless device or transvenous lead, BiVP pacing—biventricular pacing, HB pacing—His bundle pacing, LBBAP pacing—left bundle branch area pacing, Combined pacing – left bundle branch optimized cardiac resynchronization therapy (LOT-CRT) and his bundle optimized cardiac resynchronization therapy (HOT-CRT) Table 2Ongoing randomized trials evaluating conduction system pacingNCT numberClinical scenarioLVEF criterionPlanned NCSP modalityComparatorPrimary endpointEstimated completion/reportingStatus/commentRVP/minimized VP comparator PROTECT-HFNCT05815745Bradycardia requiring ventricular pacingLVEF > 35%2600CSP (HBP or LBBAP)RVPDeath and unplanned HF acute care (HF hospitalization or ambulatory IV diuretic therapy)Primary completion ~ 2029; reporting 2030–2031Large hard-endpoint trial; recruiting PhysioVP-AF [34]NCT05367037SND or paroxysmal AV block with prolonged PR intervalExcludes CRT/ICD candidates640CSP (HBP or LBBAP)RVP with managed ventricular pacingOccurrence of persistent AFCompletion ~ 2028; reporting 2029–2030Active recruiting; comparator is minimized ventricular pacing rather than high-burden RVP PHYSPAVBNCT05214365AV block requiring pacingLVEF > 50%200CSP (HBP or LBBP)RVPPICM or admission due to HF at 12 months2026–2027Ongoing/unpublished BOSTON PACENCT05869500High-grade AV block with anticipated > 40% VPLVEF > 50%100LBBAPRVPChange in LVEF and LVESV at 12 months2026–2027Pilot feasibility trial. Recrution completed PROTECT-SYNCNCT05585411Bradyarrhythmia with anticipated > 40% VPExcludes CRT/ICD candidates450LBBAPRVPComposite of all-cause death, HFH, PICM and CRT upgrade at 2 years2027–2028Recruiting, estimated completion 2026 LEAP-BlockNCT04730921AV block with anticipated > 40% VPLVEF > = 50%486LBBAPRVPTime to first event: all-cause death, HFH, or device upgrade due to HF within 2 years of implantation2027–2028Completed LEAPNCT04595487AV conduction disorder; expected VP > = 20%LVEF > = 40%470LVSPRVPComposite of death, HF hospitalization, or > 10% absolute LVEF decrease leading to LVEF < 50% at 1 yearCompletion likely 2025; reporting 2026?Unknown status OptimPacingNCT04624763AV block/brady pacingLVEF > 35%683LBBPRVPComposite of all-cause death, HFH, and/or PICM at 6, 12, 24 and 36 monthsLikely 2028Active, not recruiting LEFT-HFNCT05015660High-degree AV block; anticipated VP > 90%LVEF > 35%1300LBBPRVPTime to CV death, first HF event at 36 months and time to worsening LVESVi at 24 monthsCompletion ~ 2026; reporting 2030Recruiting PROTECT-UPNCT06052475Upgrade from chronic RVP in mild-moderate LV impairmentLVEF 35–50%155CSP (HBP or LBBP);BVP if CSP not deliverableContinued RVPSF-36 physical component score under blinded crossover conditions2027–2028Active/recruiting; crossover design NOVEL IINCT07464041AV block with anticipated > = 40% VPLVEF > 50%200LBBAP with stylet-driven leadRVPChange in LVEF at 12 months2027–2028Recruiting LBBAP vs MVPNCT07314008Sick sinus syndrome with prolonged PR interval (> 200 ms)LVEF > 35%440LBBAPRVP with managed ventricular pacingComposite of all-cause mortality, HFH, and persistent AF at 2 years2029RecruitingBVP/CRT comparator SYNCHRONICITY/Boston Scientific LBBAP-CRTNCT07069738De novo CRT-D indication in HF with LBBBLVEF < = 35%850LBBAPBVPComposite effectiveness endpoint including death, transplant, LVAD, HF events, VT/VF requiring device intervention up to 5 years; safety endpoint, system-related complication-free rate at 12 months2029–2030Industry-sponsored trial; enrolling LEFT vs LEFTNCT05650658HF with LVEF < = 50% and wide QRS or current/anticipated high VP burdenLVEF < = 50%2136CSP (HBP or LBBAP)BVPComposite of all-cause mortality and HF hospitalization (5,5 years FU)Primary completion ~ 2029; reporting 2030Recruiting CONSYST-CRT IINCT06105580Symptomatic HF with CRT indication or brady pacing indicationLVEF < = 35% for CRTLVEF < 40% for brady320CSP (HBP or LBBAP)BVPComposite of all-cause mortality, cardiac transplant, or HF hospitalization at 12 monthsPrimary completion Nov 2027; reporting 2028Larger clinical-endpoint successor to CONSYST-CRT HIS-ALT IINCT04409119/NCT05814263Symptomatic HF with typical LBBB (CRT indication) or need for upgrade of existing deviceLVEF < = 35%150CSP (HBP or LBBAP)BVPChange in LVESV/feasibility of QRS narrowingReporting likely 2027Main trial plus UK-site registration. Completed 2026 HIS-CRTNCT05265520HF with RBBB requiring CRTLVEF < = 35%120HBPBVPChange in LVEF at 6 months2027–2028RBBB-specific CRT trial. Recruiting LeCaRTNCT05365568CRT-indicated HFLVEF < 40%170 planned; 168 randomizedLBBAPBVPComposite: death, HF hospitalization, device-related reintervention, or failure to deliver assigned CRTPresented 2026; full paper likely 2026–2027Completed NORDIC-CSPNCT07492979CRT, upgrade or brady pacing indicationLVEF < = 40%1100CSP (HBP or LBBAP)BVPComposite of time to death or first non-planned HF hospitalisation2031New 2026 record; not yet recruiting DA VINCINCT07107048CRT indication, LBBBLVEF < = 35%194LBBAPBVPCRT response: freedom from cardiac death, HFH, ≥ 15% relative reduction in left ventricular end-systolic volumeCompletion estimated 2027Not yet recruiting CSP vs surgical LVNCT06342492Patients that underwent CRT with BVP and failed CS implantationNot specified (LVEF < 40%?)100CSPtransthoracic epicardial LV lead placementNeed for lead revisionEstimated completion 2024?Recruiting BATTLENCT06061627Patients with HF, CRT indication and IVCDLVEF < = 35%86LOT-CRTBVPChange in LVEF at 6 monthsEstimated completion 2027Recruiting ACHIEVED LBBAPNCT07526896Patients with HF, CRT indication, and LBBB (Strauss criteria)LVEF < = 35%80LBBAPLOT-CRTChange in LVEF and LVESV at 6 and 12 months; crossover designEstimated completion 2029New, not yet recruiting, Industry sponsored AF/pace-and-ablate or non-pacing comparator CONDUCT-AFNCT05467163HF + symptomatic AF, narrow QRS, pace & ablate strategyLVEF < 50%82CSP (HBP or LBBAP)BVPChange in LVEF at 6 monthsPresented 2026; full paper likely 2026Completed APAF-CSPNCT07604727Symptomatic HF + AF unsuitable for rhythm control; pace & ablate strategyAcross EF292CSP (HBP or LBBAP)BVPHierarchical composite: all-cause mortality, HF hospitalization/urgent HF visit, and > = 5-point KCCQ improvement (mean FU 2,5 years)New 2026 registration; likely 2030 + Broad pace-and-ablate implementation trial PACE-FIB [35]NCT05029570Permanent AF + HFLVEF > 40%334CSP + AVNAOptimal medical/pharmacological therapyComposite of all-cause mortality, HFH, and worsening HF (36 months)2030Recruiting RAFT-P&ANCT06299514Symptomatic HF with permanent/persistent AF; pace & ablate strategyAcross EF600CSP + AVNAOptimal medical/pharmacological therapyComposite/hierarchical objective including mortality, HF hospitalization, NT-proBNP and QoL (Winratio)Completion 2029, reporting 2030–2031Recruiting ABACUS [36]NCT06207383Persistent AF with HF; eligible for AF ablation or CSP + AVNAAcross EF220CSP + AVNAAF catheter ablation/PVICo-primary endpoints: superiority for mortality + CV hospitalization and non-inferiority for mortality + HF hospitalization (1–4 years)Completion 2028; reporting 2029Recruiting AVENUE PACENCT07059208Persistent AF > 65 years or paroxysmal AF > 75 years, HR > 70bpm on resting ECG, failed pharmacological therapyAcross EF172CSP + AVNAPVIAll cause rehospitalisation (2 years)Completion 2029; reporting 2031Not yet recruiting AVA CONDUCTNCT07428967Symptomatic AF with scheduled AVNALVEF = > 50%82LBBAP + AVNARVP + AVNANo. developing PICM at 36 monthsCompletion 2028; reporting 2029Recruiting HF-RELIEFNCT06833138Permanent AF, = > 1 HF hospitalisation in previous year, narrow QRS, average HR < = 110 bpm = > 50%266CSP + AVNAOptimal medical/pharmacological therapyTime to composite of all-cause mortality, HF hospitalisation or IV diuretics (24 months)December 2029RecruitingHFpEF ELEVATE-HFpEFNCT06678841Symptomatic HFpEF without an established pacing indication; personalized accelerated pacing = > 50%700Personalized accelerated pacingPacing OFFTime to the composite of all-cause death, HF hospitalization, or HF worsening requiring IV diuretics at 12 monthsCompletion 2029RecruitingThe table summarizes ongoing, recently completed, or not-yet-fully-published randomized trials evaluating conduction system pacing in bradycardia pacing, cardiac resynchronization therapy, upgrade procedures, and pace-and-ablate strategies. Trials are grouped by comparator: right ventricular pacing/minimized ventricular pacing, biventricular pacing/cardiac resynchronization therapy, and atrial fibrillation/pace-and-ablate or non-pacing comparators. Trial characteristics, LVEF criteria, planned sample size, pacing modality, comparator, primary endpoint, estimated reporting timeframe, and status are shown. Trial details should be verified against the original registry record before manuscript submissionAF atrial fibrillation, AV atrioventricular, AVNA atrioventricular node ablation, BVP biventricular pacing, CRT cardiac resynchronization therapy, CSP conduction system pacing, CV cardiovascular, EF ejection fraction, FU follow-up, HBP His bundle pacing, HF heart failure, HFH heart failure hospitalization, ICD implantable cardioverter-defibrillator, KCCQ Kansas City Cardiomyopathy Questionnaire, LBBAP left bundle branch area pacing, LBBB left bundle branch block, LBBAP left bundle branch pacing, LV left ventricular, LVAD left ventricular assist device, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVESVi left ventricular end-systolic volume index, LVSP left ventricular septal pacing, MVP minimized ventricular pacing, NCT National Clinical Trial number, NT-proBNP N-terminal pro-B-type natriuretic peptide, PICM pacing-induced cardiomyopathy, PVI pulmonary vein isolation, QoL quality of life, RBBB right bundle branch block, RVP right ventricular pacing, SND sinus node dysfunction, VF ventricular fibrillation, VP ventricular pacing, VT ventricular tachycardia Ongoing randomized trials evaluating conduction system pacing CSP (HBP or LBBP); BVP if CSP not deliverable LVEF < = 35% for CRT LVEF < 40% for brady The table summarizes ongoing, recently completed, or not-yet-fully-published randomized trials evaluating conduction system pacing in bradycardia pacing, cardiac resynchronization therapy, upgrade procedures, and pace-and-ablate strategies. Trials are grouped by comparator: right ventricular pacing/minimized ventricular pacing, biventricular pacing/cardiac resynchronization therapy, and atrial fibrillation/pace-and-ablate or non-pacing comparators. Trial characteristics, LVEF criteria, planned sample size, pacing modality, comparator, primary endpoint, estimated reporting timeframe, and status are shown. Trial details should be verified against the original registry record before manuscript submission AF atrial fibrillation, AV atrioventricular, AVNA atrioventricular node ablation, BVP biventricular pacing, CRT cardiac resynchronization therapy, CSP conduction system pacing, CV cardiovascular, EF ejection fraction, FU follow-up, HBP His bundle pacing, HF heart failure, HFH heart failure hospitalization, ICD implantable cardioverter-defibrillator, KCCQ Kansas City Cardiomyopathy Questionnaire, LBBAP left bundle branch area pacing, LBBB left bundle branch block, LBBAP left bundle branch pacing, LV left ventricular, LVAD left ventricular assist device, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVESVi left ventricular end-systolic volume index, LVSP left ventricular septal pacing, MVP minimized ventricular pacing, NCT National Clinical Trial number, NT-proBNP N-terminal pro-B-type natriuretic peptide, PICM pacing-induced cardiomyopathy, PVI pulmonary vein isolation, QoL quality of life, RBBB right bundle branch block, RVP right ventricular pacing, SND sinus node dysfunction, VF ventricular fibrillation, VP ventricular pacing, VT ventricular tachycardia Current evidence for devices in cardiac resynchronization therapy Cardiac resynchronization therapy is an established treatment for patients with HF, reduced LVEF, and LBBB. Traditionally, CRT has been synonymous with BVP. Several studies and large randomized clinical trials have consistently demonstrated that CRT improves cardiac function, promotes reverse ventricular remodelling and improves outcomes [12, 13, 38, 39]. Despite robust evidence supporting its efficacy, BVP has some limitations. These include anatomical constraints of the coronary venous system that may hinder optimal lead placement, phrenic nerve stimulation, and potentially incomplete electrical resynchronization with increased risk of arrhythmias [40–43]. To overcome some of the limitations associated with conventional BVP, leadless LV endocardial pacing has been developed as an alternative resynchronization strategy. The WiSE-CRT system (Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy) delivers ultrasound-mediated energy from a subcutaneously implanted transmitter and battery to a leadless LV endocardial electrode, enabling physiological LV endocardial stimulation without the need for a coronary sinus lead. Despite the proven feasibility of this approach, widespread clinical adoption has been limited by several important drawbacks, including high device costs, notable complication rates, and the potential need for prolonged anticoagulation [44]. Several smaller randomized studies conducted in experienced centers demonstrated non-inferiority of LBBAP compared with BVP in CRT candidates. However, these trials primarily assessed surrogate endpoints, such as echocardiographic reverse remodelling and QRS narrowing, rather than hard clinical outcomes [45–47]. In contrast, more recent multicenter randomized trials assessing hard clinical outcomes alongside surrogate measures have yielded conflicting results. The HeartSync-LBBP randomized trial, which enrolled 200 CRT patients across six experienced centers in China, demonstrated superiority of LBBAP over BVP for the composite endpoint of all-cause mortality and HF hospitalization when a highly selective criteria of LBBB correctable by His bundle pacing was used in the LBBAP arm, thus identifying a specific subgroup of patients with LV “dyssynchronopathy” [48]. In contrast, two similarly sized multicenter trials failed to demonstrate non-inferiority of LBBAP compared with BVP [49, 50]. In the Brazilian PhysioSync-HF trial, conducted across 14 centers where only 57% of operators had experience with more than 40 CSP procedures, CSP was inferior to BVP with respect to the hierarchical primary endpoint of all-cause mortality, HF hospitalization, and LVEF improvement [49]. Although several factors may have contributed to these findings, including a heterogeneous patient population and crossover between treatment groups, differences in CSP technique likely played a major role, as only 69% of patients received LBBAP in PhysioSync-HF compared with 98% in HeartSync-LBBP. Similarly, the Spanish multicenter LEFT-BUNDLE CRT trial failed to demonstrate non-inferiority of LBBAP versus BVP; however, the exceptionally high CRT response rate (defined either by an improved clinical composite score or ≥ 15% reduction in left ventricular end-systolic volume at 6-month follow-up) in the BVP arm and a relatively high crossover rate (20.7%) may have limited the ability to establish non-inferiority of this novel pacing modality [50]. Moreover, about 50% of patients were classified as having LV septal pacing rather than conduction system engagement, thus making the clinical value of true LBBAP difficult to assess. However, it should be noted that contemporary randomized CRT trials have set the benchmark for CRT echocardiographic response at 77–80% and clinical response at 90% (all-cause mortality < 4% yearly, CV hospitalizations < 10% yearly) [12, 13, 38, 39]. Thus, while the LEFT-Bundle CRT trial outcome was reasonably expected, the 28% HF hospitalizations rate observed in the HeartSync-LBBP [48] CRT arm remains unexplained (4 –fold higher compared to the literature) and possibly reflects selection bias in light of the 90% correctability of LBBB observed in the LBBAP arm. As guidelines and consensus documents increasingly endorse CSP as an alternative to conventional BVP [4, 5], these mixed findings highlight the need for cautious and selective implementation. Differences among contemporary randomized trials likely reflect a combination of methodological and clinical factors, including patient selection, baseline degree of conduction system disturbances resulting in LBBB, operator experience, definitions of conduction system capture versus left ventricular septal pacing, crossover rates, endpoint selection, and follow-up duration. Importantly, these discrepancies may also reflect genuine uncertainty regarding whether improved electrical resynchronization consistently translates into superior clinical outcomes across all CRT-eligible patients. Ongoing and future multicenter randomized trials (Table 2) with standardized implantation criteria, rigorous confirmation of conduction system capture, and long-term clinical endpoints will be essential to better define the role of CSP in CRT candidates. Ultimately, reconciling these divergent findings may refine patient selection and optimize CRT delivery, potentially through combined approaches such as left bundle branch optimized CRT (LOT-CRT) [51] (Fig. 1). Treatment strategies and management of atrial fibrillation in heart failure Atrial fibrillation (AF) is characterized by disorganized atrial activity and an irregular, rapid ventricular response, leading to reduced cardiac output (CO) and hemodynamic impairment [52–55]. Restoration of ventricular rate control and regularity can improve hemodynamics and symptoms. Two main therapeutic strategies are available: rhythm and rate control. Rhythm control can be achieved with antiarrhythmic drugs and/or catheter ablation (CA), aiming to restore sinus rhythm (SR) and atrial contribution to CO. In patients with HF, CA has shown superiority over GDMT therapy in improving outcomes, with the CASTLE-AF trial demonstrating reductions in mortality and hospitalizations for worsening HF [56–59]. Accordingly, current European and US guidelines recommend CA as first-line therapy in HF patients with AF [60, 61]. However, the success rates of rhythm control strategies in patients with persistent forms of AF are limited [62, 63]. Data in patients with recurrent AF, the elderly, and those with multiple comorbidities remains scarce, particularly regarding the risks of repeat procedures and associated complications. In this subset of patients who cannot be adequately rate-controlled with medical therapy and in whom rhythm control has failed or is not appropriate, atrioventricular node ablation (AVNA) followed by pacemaker implantation (‘pace-and-ablate’) offers a safe and effective alternative, ensuring reliable rate control, regularization of ventricular rhythm, elimination of rate-control medications, and rapid symptomatic relief [64]. The choice between catheter ablation and a pace-and-ablate strategy should be individualized according to the underlying AF phenotype and likelihood of successful rhythm control. Catheter ablation should be prioritized in patients with AF-mediated cardiomyopathy or a high likelihood of maintaining sinus rhythm, whereas ‘pace-and-ablate’ strategy represents a reasonable alternative in older patients with long-standing persistent or permanent AF, multiple comorbidities, failed rhythm-control attempts, or inadequate rate control. A recent meta-analysis evaluating five principal treatment strategies for AF found that CA was most effective in preventing AF recurrence, whereas the pace-and-ablate approach was associated with lower mortality and fewer rehospitalizations [65]. Current ESC and US guidelines recommend AVNA in patients with refractory rapid ventricular response who are unresponsive or intolerant to intensive rate and rhythm control therapy, and not eligible for rhythm control by CA (Class IIa, Level of evidence B) [60, 61]. The management pathway therefore involves two sequential decisions: whether catheter ablation is likely to achieve durable rhythm control and, if a pace-and-ablate strategy is pursued, selecting the pacing modality that best preserves physiological ventricular activation and long-term ventricular function, as pacemaker dependency makes this choice a key determinant of clinical outcomes. When combined with AVNA, RVP has been shown to improve several clinically relevant outcomes, including symptoms, quality of life, exercise capacity, and LVEF [66]. However, the principal long-term concern after AVNA is pacing-induced dyssynchrony from conventional RVP, which can precipitate or worsen preexisting HF [64, 67, 68]. The deleterious effects of RVP can be mitigated by BVP, which, according to randomized trials, including APAF-CRT study, and meta-analyses, when combined with AVNA, leads to reductions in mortality, HF hospitalizations, and adverse LV remodelling [69–71]. Therefore, ESC guidelines provide a Class I recommendation for BVP in patients with reduced LVEF undergoing AVNA, and a Class IIa recommendation in those with mildly reduced LVEF, whereas US guidelines assign a Class IIa recommendation in patients with reduced LVEF < 50% to avoid pacing-induced dyssynchrony [2, 5]. However, BVP does not fully restore physiological activation and remains associated with QRS prolongation and residual electrical and mechanical dyssynchrony [72]. CSP is a feasible alternative to conventional RVP and BVP. Compared to initial experience with HBP, LBBAP is less affected by the ablation site, shows more stable long-term parameters without the need of a RV back-up lead, and therefore represents a more practical physiological alternative [73]. Several observational studies have already reported greater symptomatic and echocardiographic improvement with CSP after AVNA, compared with BVP, particularly in those with narrow baseline QRS and reduced EF [74, 75] To date, the only randomized study in this setting, the ALTERNATIVE-AF trial, proved significant improvement in LVEF with HBP compared with BVP in patients with persistent AF, reduced LV function, and narrow QRS [76]. A recent meta-analysis further suggests that CSP achieves narrower QRS duration with similar clinical and echocardiographic outcomes and no survival benefit over BVP [77]. Data in patients with preserved EF and no HF diagnosis are lacking. European And US pacing guidelines consider a Class IIb alternative to BVP in patients undergoing AVNA, with no formal recommendation for LBBAP at that time, whereas the latest 2025 ESC consensus statement provides a stronger endorsement of CSP use across all EF ranges to preserve or improve LV function and HF outcomes [2, 4, 5]. Several ongoing trials (Table 2) will further illuminate the role of pace-and-ablate strategy in HF patients with AF, including randomized comparisons of pace-and-ablate with CSP versus medical rate control (RAFT P&A trial), head-to-head comparisons of CSP versus BVP following AVNA (CONDUCT-AF trial), and comparisons of CA versus pace-and-ablate strategy (ABACUS trial). However, definitive randomized evidence from these studies is still awaited [36, 78]. Current and emerging devices for prevention of sudden cardiac death in heart failure SCD rate in HF patients due to systolic dysfunction is substantially unchanged despite GDMT [79]. SCD prevention strategy stands on trials adopting TV-ICD devices and no comparison of TV vs non-transvenous ICDs is available [80–83]. Thus, inference must be taken by the subgroups of patients with HF (EF < 35%) enrolled in non-TV-ICD studies. Subcutaneous ICD (S-ICD) offers superior immunity by lead-related complications compared to TV-ICD, albeit suffering the lack of ATP, which can be significantly helpful for painless monomorphic VT termination [84, 85]. S-ICD has substantial data available proving a similar efficacy to TV devices for the termination of life-threatening ventricular arrhythmias (VA) in HF patients: 3 large registries report similar efficacy, complication rate, and inappropriate shock rate compared to TV devices [86–88]. However, only one study reported a real-life comparison of S-ICD and TV-ICD recipients in a mixed population with high prevalence of HF and a mean age above 70 years, showing similar all-cause mortality, all-cause and cardiovascular readmissions, and reoperation rate with or without device infection. Thus, it appears that the S-ICD is neither burdened by device-deficiency nor offers any significant advantage in a real-life HF population. In this respect, a modular system combining a leadless unit to deliver ATP with the S-ICD has been developed, reporting a 61% efficacy to terminate clinical arrhythmias by ATP. This reinforces the approach to provide a comprehensive technology to treat VA, rather than shock-only devices [89]. However, the timing and opportunity of this modular approach is highly debatable, as recurrent MVT in S-ICD recipients may be more likely treated by VT ablation and/or antiarrhythmic drugs rather than by addition of a leadless unit to deliver ATP [90]. The extravascular ICD (EV-ICD) addresses this task owing to lead placement in the anterior mediastinum to reliably detect VAs, enabling termination either by ATP or shock [91]. In the post marketing registry, the EV-ICD has demonstrated efficacy and inappropriate shock rate similar to the S-ICD [92]. Though rapidly spreading in the clinical use, HF patients are underrepresented in the 2 largest publications, accounting for about 30% of patients [92, 93]. The advantage of the EV-ICD stands in its smaller size and extended longevity compared to the S-ICD, which makes it fit also for paediatric and small-habit patients [94]. Notably, EV-ICD is a reliable alternative for patients unsuitable to an S-ICD but is contraindicated in patients with previous sternotomy. Both the S-ICD and the EV-ICD offer the unique possibility of a modular approach to HF patients who firstly require the SCD prevention strategy, than develop indication to either CRT or brady-arrhythmia treatment: a number of case series or case reports has demonstrated the safe coexistence of non-communicating devices implanted in the same patient with an S-ICD without untoward interferences: either TV, leadless and epicardially-implanted leads [95]. CSP co-implanted with an S-ICD has also proven to be feasible in the complex scenario of HBP. Non-communicating CRT and leadless pacemakers have been implemented safely with the EV-ICD, and in-silico model do not show significant interaction [96]. Eventually, owing to the availability of leadless pacemakers and CRT (possibly of CSP), non-TV-ICD offer the ideal platform for defibrillation backup in totally leadless bradyarrhythmia treatment, CRT, and even CSP [97, 98]. This approach aims to minimize the amount of intravascular burden and/or to overcome the challenges and the risks of system upgrading [99]. In the contemporary setting, individualized treatment by communicating or non-communicating devices is feasible depending on patient’s profile at presentation (Fig. 2). Comparison of implantable cardioverter-defibrillator systems with considerations for clinical decision-making is summarized in Table 3. Sudden cardiac death prevention therapies in heart failure. Spectrum of current devices used for the prevention of sudden cardiac death in patients with heart failure. Transvenous implantable cardioverter-defibrillator – TV-ICD, subcutaneous ICD—S-ICD, extravascular ICD—EV-ICD and modular S-ICD with leadless pacemaker for antitachycardia pacing (ATP) delivery Table 3Comparison of implantable cardioverter-defibrillator systems with considerations for clinical decision-makingTransvenous ICD(TV-ICD)Subcutaneous ICD(S-ICD)Extravascular ICD(EV-ICD)Modular ICD(mCRM)Lead locationTransvenous (RV ± RA)Subcutaneous, parallel to sternumSubsternal (extravascular)Combination of EV-ICD and leadless pacemakerVascular access requiredYesNoNoYesDefibrillation energy20–40 JUp to 80 J ~ 40 J ~ 40 JATP capabilityYesNoYesYesBradycardia pacingYesLimited post-shock onlyTemporary post-shock pacingFull leadless pacingVT managementATP and shocksShocks onlyATP and shocksATP and shocksLead extraction complexityModerate–highLowExpected lower than TV leadsUnknownRisk of bloodstream infection/endocarditisHighestVery lowLowVery lowRisk of pneumothoraxYesNoNoNoRisk of venous occlusionYesNoNoNoLead fracture riskHighLowUnknownUnknownBattery longevity7–12 years8–10 yearsUnknownUnknownIdeal candidatesNeed for pacing, ATP, or CRTYoung patients without pacing indication, high infection risk or difficult venous accessNeed ATP but wish to avoid transvenous leadsPatients requiring both defibrillation and pacing without transvenous leadsAnatomical considerationsUsually not limitingChallenging in very low BMI or unfavorable thoracic anatomySubsternal anatomy and prior thoracic surgery may influence suitabilitySimilar considerations as EV-ICD and leadless implantationLikelihood of future CRT requirementPreferredLess suitableLess suitableLess suitable (no integrated CRT)Current evidence baseStandard of care with the broadest evidence across HF populationsEstablished for appropriately selected patients without pacing indicationEarly clinical experience; long-term comparative data remains limitedEarly clinical experience; evidence remains limitedATP antitachycardia pacing, CRT cardiac resynchronization therapy, EV-ICD extravascular implantable cardioverter-defibrillator, ICD implantable cardioverter-defibrillator, J-joules mCRM-modular cardiac rhythm management, RA right atrium, RV right ventricle, S-ICD subcutaneous implantable cardioverter-defibrillator, TV-ICD transvenous implantable cardioverter-defibrillator, VT ventricular tachycardia Comparison of implantable cardioverter-defibrillator systems with considerations for clinical decision-making ATP antitachycardia pacing, CRT cardiac resynchronization therapy, EV-ICD extravascular implantable cardioverter-defibrillator, ICD implantable cardioverter-defibrillator, J-joules mCRM-modular cardiac rhythm management, RA right atrium, RV right ventricle, S-ICD subcutaneous implantable cardioverter-defibrillator, TV-ICD transvenous implantable cardioverter-defibrillator, VT ventricular tachycardia New indications for treatment of heart failure with cardiac implantable electronic devices Pacing in prolonged PR interval First degree AV block has traditionally been regarded as a benign finding. However, large population-based studies have demonstrated that PR interval prolongation is associated with an increased risk of AF, pacemaker implantation, HF, and cardiovascular death [100, 101]. Mechanistically, PR prolongation may impair ventricular filling by fusing diastolic phases and promoting diastolic mitral regurgitation, thereby reducing end-diastolic volume and producing HF–like symptoms. This condition, previously termed pseudo-pacemaker syndrome, is now more accurately described as AV dromotropathy [102]. Current guidelines recommend pacing in symptomatic patients with marked PR prolongation (> 300 ms) (Class IIa, Level of Evidence C), without specifying pacing modality or LVEF [2]. Early studies using RVP in this setting yielded limited benefit [103, 104]. In contrast, sub-analyses of CRT trials showed that PR prolongation identifies a higher-risk subgroup, with increased rates of HF progression and mortality; notably, this excess risk appeared attenuated following CRT, suggesting that optimisation of AV coupling may improve outcomes [105] [106]. A combined computational and clinical study reported a 10–15% increase in cardiac output with restoration of AV coupling with unchanged ventricular activation; however, this benefit was attenuated by RVP-induced ventricular dyssynchrony, supporting the use of CSP in this setting [107]. A randomized cross-over study comparing AV-optimised HBP with back-up pacing in patients with prolonged PR and reduced LVEF failed to demonstrate an increase in peak oxygen uptake but was associated with better quality of life and patient preference for active pacing [108]. In patients with preserved LVEF, AV-optimised His bundle pacing has been associated with symptomatic improvement, increased stroke volume and a trend toward improved exercise capacity [109]. Patient selection remains challenging, as the degree of PR prolongation alone appears to be a poor predictor of response [110, 111]. Given the high prevalence of first-degree AV block—1–2% in the general population and up to 50% among CRT candidates—there is substantial therapeutic potential. Larger outcome-driven studies (Table 1 and 2) are needed to define the role of pacing for AV recoupling. Pacing in heart failure with preserved ejection fraction In contrast to HF with reduced ejection fraction, where beta-blockers and heart rate reduction improve outcomes, this strategy has not shown benefit in HF with preserved ejection fraction (HFpEF). In fact, withdrawal of beta blockers in a small study of patients with HFpEF was associated with a reduction in natriuretic peptide (NT-proBNP) levels [112]. Similar benefit was demonstrated in a small pilot study using pacing at 80 bpm, suggesting that moderately higher heart rates might reduce LV filling pressures by shortening diastole in a stiff, non-compliant LV [113]. These findings were supported by the first randomized study in HFpEF patients with pacemakers, where personalized accelerated pacing improved quality of life and physical activity, reduced NT-proBNP, and lowered device-detected atrial fibrillation at 1 year compared to usual care [114]. Benefits appeared greater in patients with smaller LV volumes and higher LVEF [115]. Longer-term follow-up (~ 2 years) demonstrated changes in LV geometry, including reduced wall thickness, mild dilatation, and a small reduction in LVEF [116, 117]. Mechanistic studies further suggest that moderate increases in pacing rate lower left atrial pressure, whereas higher rates may be counterproductive due to AV interval prolongation [118]. Bachmann bundle pacing, intended to preserve more synchronous atrial activation, has shown favourable effects on biomarkers, diastolic parameters and exercise capacity [119]. Evidence supporting pacing-based treatment strategies in heart failure with preserved ejection fraction (HFpEF) thus remains preliminary, evaluating haemodynamic, biomarker, functional, and patient-reported endpoints. Potential risks include device infection, atrial arrhythmias, and uncertain long-term effects of sustained pacing on ventricular structure and function. Validation is awaited from the ongoing ELEVATE-HFpEF study (NCT06678841), randomizing ~ 700 HFpEF patients to personalized accelerated conduction system pacing—preferentially targeting the Bachmann bundle—versus no or minimal pacing, with clinical outcomes as primary endpoints. Implantable devices in heart failure monitoring Monitoring of HF with Transvenous CIEDs Despite major advancements in GDMT, the burden of worsening HF remains substantial, and contemporary data demonstrate that nearly half of worsening HF events occur outside the hospital–in emergency departments, observation units, and ambulatory clinics [120]. Trial evidence (STRONG-HF) and new outpatient diuretic options (subcutaneous furosemide, intranasal bumetanide) have accelerated a shift toward managing HF in the ambulatory setting, creating an urgent need for remote patient monitoring (RPM) strategies that can detect hemodynamic congestion before clinical deterioration [121]. Traditional surveillance using symptoms, vital signs, and body weight is well known to lack sensitivity for early decompensation, motivating sensor- and algorithm-based approaches that exploit existing CIEDs [122, 123]. Two parallel advances have made CIED-based monitoring increasingly attractive. First, modern ICDs and CRT pacemakers/defibrillators now carry multiple physiologic sensors–heart sounds (S1/S3), intrathoracic impedance, respiratory rate, heart rate variability, and patient activity—already in place for guideline-indicated therapy [122, 123]. Second, machine learning approaches have made it possible to fuse these channels into composite, personalized indices that outperform any single biomarker for the detection of impending decompensation [122]. Conceptually, two device classes have emerged: (1) sensors integrated into existing therapeutic CIEDs and (2) dedicated implants placed solely for monitoring. Each carries a distinct evidentiary threshold: dedicated implants incur procedural risk and therefore require stronger evidence of net clinical benefit, whereas integrated diagnostics piggyback on an already-indicated device and can be activated remotely (Fig. 3). Two paradigms of CIED-based heart failure monitoring. A Multi-sensor algorithms (e.g., HeartLogic) leverage physiologic sensors already present on existing ICDs and CRT-Ds; pivotal evidence comes from the MultiSENSE study with the ongoing DANLOGIC-HF RCT [122–124]. B Dedicated hemodynamic implants (CardioMEMS, Cordella) directly measure pulmonary artery pressure; pivotal evidence comes from the CHAMPION trial, with mixed signals from GUIDE-HF and supportive single-arm data from PROACTIVE-HF [125–128] Early single-sensor strategies–most notably the OptiVol intrathoracic impedance index—produced disappointing results in randomized trials (DOT-HF, OptiLink HF), in large part because impedance changes lack specificity and generated frequent false alerts [129, 130]. The HeartLogic algorithm (Boston Scientific) represents the contemporary multi-sensor evolution of this approach [122, 123]. In the MultiSENSE study (N = 900 CRT-D recipients), HeartLogic detected 70% of HF events at a median of 34 days before the event, providing a clinically actionable lead time [122]. Real-world cohorts have since reported reductions in HF hospitalizations when alerts triggered structured clinical action [131–133]. Detection of alerts alone is not sufficient to reduce HF hospitalizations. To prevent worsening HF events, these physiologic sensor alerts must be reviewed promptly, interpreted in clinical context, and linked to an effective therapeutic response. A recent meta-analysis of 6 RCTs evaluating HF management guided by remote multiparameter monitoring found that this strategy reduced rates of heart failure hospitalization and all-cause mortality [134]. These benefits reflect not only improved detection of impending decompensation but also the ability to translate alerts into targeted HF management. The first adequately powered randomized trial of HeartLogic-guided care, DANLOGIC-HF (NCT06099158), is a pragmatic Danish registry-based RCT enrolling 1,428 patients with completion expected in 2027 [124]. Although uptake in routine practice has lagged the underlying technology, the convergence of high-fidelity device sensors, mature ML algorithms, and the policy imperative to keep patients at home is now driving meaningful integration of CIED-based monitoring into HF care pathways. The evidence for implantable sensors to monitor HF The most extensively studied dedicated implant is the CardioMEMS HF System (Abbott), a wireless pulmonary artery (PA) pressure sensor [125]. In the pivotal CHAMPION trial, 550 patients with NYHA class III HF and a prior HF hospitalization were randomized to PA pressure-guided management versus usual care [125]. PA-guided care reduced HF hospitalizations by 37% at 6 months and by 33% over the entire randomized follow-up, with benefit observed across the ejection fraction (EF) spectrum [125, 126]. The subsequent GUIDE-HF trial was neutral for the overall composite endpoint, although a pre-COVID analysis showed a 19% reduction driven by HF hospitalizations [127]. The Cordella Heart Failure System (Endotronix) is a second-generation PA sensor that also integrates daily vital signs, weight, and patient-reported symptoms; the PROACTIVE-HF trial reported a lower-than-expected HF hospitalization and mortality rate among device recipients, supporting FDA approval, though the single-arm performance-goal design limits causal inference [135]. Earlier-stage devices in development include left atrial pressure sensors (V-LAP) and inferior vena cava–based volume sensors. Taken together, CIED-based monitoring has progressed from single-channel impedance alerts to validated multi-sensor algorithms and to dedicated hemodynamic implants with RCT evidence of benefit. Important gaps remain, procedural risk and cost for dedicated implants, alert fatigue and the absence of standardized response protocols for both categories, and limited representation of women, racial and ethnic minorities, and HFpEF patients in pivotal trials. The next generation of evidence–exemplified by DANLOGIC-HF and post-PROACTIVE-HF studies–should move beyond sensitivity and specificity to test, in adequately powered randomized trials with hard endpoints, whether acting on these signals with structured response protocols reduces HF hospitalization and mortality in real-world practice [131, 135]. CIED-based monitoring is most powerful when paired with rapid GDMT optimization and outpatient diuretic strategies–synergy, not substitution. Cardiac implantable electronic device procurement across Europe and real-world implementation Globally, the conservative estimate is that at least 55 million people live with heart failure, and within Europe more contemporary assumption is exceeding 30 million patients [136, 137]. These numbers are increasing in last decades and pose a huge (unmet) challenge for modern medicine. Nonetheless, they also give stage for effective pharmacological and non-pharmacological therapy. Cardiac implantable electronic devices should be integrated into comprehensive HF management rather than viewed as stand-alone therapies. Device selection and timing should be coordinated with optimization of GDMT, particularly in ischemic cardiomyopathy, where β-blocker optimization or intolerance may influence arrhythmic risk, pacing requirements, and ICD or CRT decision-making. This integrated approach is especially relevant for CRT candidacy, ICD timing after myocardial infarction, reverse LV remodelling, and patients with bradycardia limiting optimization of medical therapy [138]. There is abundant evidence about suboptimal pharmacotherapy in HF, that spills over to CIED as evident from contemporary implantation statistics [139, 140]. As for all CIED, the heterogeneity persists also for HF specific devices, i.e. CRT, ICD and CSP, generally with ratio of 50 or more between countries with highest vs lowest rate of implantation. The decision about patient management always is with the attending clinician, and there are individual specifics in terms of perceptions, beliefs, attitudes and strategies that influence guideline interpretation and implementation [141]. At large, delay in pharmacological therapy delivery beyond 3–6 months and traditional drug sequencing strategies instead of simultaneous initiation appear to be most important challenges to tackle, and at least in part driven by objective reasons (e.g. hypotension, hyperkalaemia, and renal function worsening by patient worsening) or simply by patient non-adherence. As all these aspects prevent timely and evidence-based CIEDs use, the scientific community is developing the strategies to overcome therapeutic inertia through a comprehensive framework using up-to-date evidence and modern technologies [7]. These must be followed also once CIED is implanted. These pacing modalities generally should improve patient haemodynamic, abolish the bradycardia risk and therefore enable for therapy introduction and/or up-titration [142]. There may be many reasons for the current CIED implantation rates, including failure to implement guideline directed therapy, staff, reimbursement, and health policy in general. Many of these can be controlled with better and focused organisation yet some can truly be out of the community reach. A sobering message regarding the financial aspects can be extracted from a recent overview about public procurement practices in 22 European countries, that demonstrated heterogeneity with general lack of value-based principles, and limited integration of patient reported and clinical outcome into decision models [143]. On the other hand, it also identified procedures and structures that can instruct for optimization of value-based decision making across Europe. Conclusions Cardiac implantable electronic devices have become an integral component of contemporary HF management, but their future lies not simply in technological innovation, but in delivering the right device to the right patient at the right time. Although advances in CSP, leadless technologies, and non-transvenous ICD systems have expanded therapeutic options, their widespread adoption should be guided by robust evidence demonstrating improvements in hard clinical outcomes beyond surrogate measures of electrical or echocardiographic response. Equally important is the integration of device therapy with GDMT and multidisciplinary heart failure care to maximize patient benefit. Finally, addressing persistent disparities in device utilization, improving timely referral, and ensuring equitable implementation of evidence-based therapies will be essential to fully realize the potential of CIEDs to improve outcomes in patients with HF. Authors’ contributions D.Ž. wrote the main manuscript text. M.M. wrote part of the manuscript text. A.Z.M. wrote part of the manuscript text. M.I. wrote part of the manuscript text. T.Ž. prepared Figs. 1—2 and Graphical abstract. C.F.B. wrote part of the manuscript text and prepared Fig. 3. A.P.A. wrote part of the manuscript text. Z.F. wrote part of the manuscript text and reviewed the manuscript. M.B. wrote part of the manuscript text and reviewed the manuscript. M.L. wrote part of the manuscript text and reviewed the manuscript. Funding The study was supported by Slovenian Research and Innovation Agency (grant nr. P03-456). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests DŽ reports receiving proctoring fees and speaker honoraria from Medtronic, Biotronik, Abbott, and Boston Scientific. AZM reports receiving proctoring fees from Abbott. MB reports educational activities and speaker bureaus on behalf of Abbott, Biotronik, Boston Scientific, Medtronic, and Philips. MM, MI, TŽ, CFB, ZF and ML have no conflicts of interest or financial ties to disclose. APA is the Editor-in-Chief. Footnotes Publisher''s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mauro Biffi and Mitja Lainscak contributed equally to this work as senior authors. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.